Rectal spacing technology can reduce radiation exposure to nontarget organs, which decreases toxicity.
A review of a series of articles published by Urology on diversity, equity, and inclusion findings in prostate cancer care.
Studies on the use of cytoreductive nephrectomy in mRCC are reviewed, including its role among TKIs and immunotherapy.
A report examines the correlation between family history of prostate cancer and risk of progression after prostatectomy.
Dr. Stacy Loeb is interviewed on the use of active surveillance for prostate cancer, its history, and new insights.
Catherine Handy Marshall reviews her career from cardiovascular disease research to prostate cancer risk factors & genetics.
The utility of using AI to help determine scoring and surgical options for kidney cancer is examined against human scoring.
18F-based PSMA imaging can provide greater spatial resolution as well as detect lesions not picked up by 68Ga-PSMA-11.
Dr Catherine Handy Marshall gives prostate cancer patients care advice beyond appointments and medical interventions.
The role of 3D modeling in the treatment of renal tumors is discussed, including developments in the technology.
Prostate cancer highlights from ASCO 2022 are discussed, including the ENZAMET trial design and TheraP trial data.
The current standard of care for patients with high-grade NMIBC, intravesical Bacillus Calmette-Guérin, is discussed.
Highlights from ASCO 2022, including the role of doublet therapy (ADT combined with a novel oral antiandrogen drug).
Michael J. Morris, MD, gives insight into his history with prostate cancer clinical research and his role in clinical trials.
Benjamin Davies, MD, gives his insight on how to reduce the use of opiates for patients after urologic surgery.
Plenary highlights from AUA 2022, including non-muscle invasive bladder cancer treatments and the SPOTLIGHT study.
Active surveillance and enzalutamide monotherapy for localized prostate cancer is compared with active surveillance alone.
The standard of care transurethral resection for bladder tumors is compared with en bloc resections for urologic procedures.
Reviewing a JAMA report on the effect of robot-assisted radical cystectomy in bladder cancer, along with the RAZOR trial.
An analysis of the HERO trial discussing the safety of relugolix, including major adverse cardiovascular events.